A Phase 1/2 interventional study of NGM120 30mg and NGM120 100mg in Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer and Bladder Cancer, sponsored by NGM Biopharmaceuticals, Inc. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-29.
Sponsored by NGM Biopharmaceuticals, Inc · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 298 open to participants now, 471 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.
Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 374th largest by enrollment of the 1,574 interventional ones that give a count, is one of 94 that started in 2019, is one of 222 in phase 1/2, and was the 1,270th registered.
3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →298 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Anova Innovation Limited · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
IMGT Co., Ltd. · Sites in United States, Korea, Republic of
Ages 18–85
AdventHealth · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,851 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 778 · Phase 2 721 · Phase 3 91 · Phase 4 12
First in 1991; this study’s year is marked. 94 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 47 across 2,935 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 1,574 interventional studies, 137 across the 230 observational. Of the 1,222 that completed or were terminated, 478 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
577 of 1,851 have an industry lead sponsor. The 10 most frequent:
NGM Biopharmaceuticals, Inc is the lead sponsor of 26 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
NGM Biopharmaceuticals, Inc has 3 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
162 of the studies in Pancreatic Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720338Phase 3Case Comprehensive Cancer CenterIs Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | 2026-12-31 |
| NCT03257033Phase 3RenovoRxIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | 2027-06 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT04275557H. Lee Moffitt Cancer Center and Research InstituteUsing Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | 2026-11 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
Add all 162 to your calendar (.ics) → With an account.
Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
The aim of the study is to evaluate the safety and tolerability of NGM120 monotherapy in subjects with select advanced solid tumors (Part 1), NGM120 in combination with gemcitabine and Abraxane for the management of metastatic pancreatic cancer (Part 2), and NGM120 in metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed under 1 or more lines of ADT (Part 3), for up to 24 months of treatment.
Inclusion Criteria (Part 1 and 2):
Inclusion Criteria (Part 3 Prostate Cancer):
Exclusion Criteria (All parts):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NGM120 30mg Subcutaneous Injection
Biological: NGM120 30mg
NGM120 100mg Subcutaneous Injection
Biological: NGM120 100mg
NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
Biological: NGM120 30mg with Gemcitabine and Abraxane
NGM120 100mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
Biological: NGM120 100mg with Gemcitabine and Abraxane
NGM120 100mg Subcutaneous Injection NGM120 100mg Subcutaneous Injection every 3 weeks
Biological: NGM120 100mg Q3W
Placebo together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
Other: Placebo
NGM120 30mg Subcutaneous Injection
NGM120 100mg Subcutaneous Injection
Drug page: Anti-GFRAL Monoclonal Antibody NGM120
NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
Drug page: Anti-GFRAL Monoclonal Antibody NGM120
NGM120 100 mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
NGM120 100mg Subcutaneous Injection every 3 weeks
Placebo
To Determine the Safety and Tolerability of NGM120 in Subjects
Number of Participants with NGM120/Placebo-Related Treatment Emergent Adverse Events
Time frame: From enrollment to end of treatment up to 24 months
To Determine the Safety and Tolerability of NGM120
Discontinuation of investigational product due to toxicity
Time frame: From enrollment to end of treatment up to 24 months
To Determine the Safety and Tolerability of NGM120
Local injection-site symptom assessment as evidenced by incidence of injection-site reactions
Time frame: From enrollment to end of treatment up to 24 months
89 patients were enrolled (signed consent), however only 87 patients received at least 1 dose of study treatment. The participant flow contains information from these 87 treated patients, that are also considered the Safety Analysis set for CSR and study results
| Milestone | Part 1 NGM120 30 mg | Part 1 NGM120 100 mg | Part 2 NGM120 30 mg | Part 2 NGM120 100 mg | Part 2 Placebo | Part 3 NGM120 100 mg |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 31 | 20 | 6 |
| Completed | 0 | 1 | 2 | 4 | 0 | 0 |
| Not completed | 10 | 9 | 8 | 27 | 20 | 6 |
| Withdrew: Adverse event | 2 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 3 | 1 | 3 | 19 | 17 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 3 | 5 | 3 | 2 | 1 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 2 | 1 | 4 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 | 2 | 1 | 0 |
| Withdrew: Symptomatic deterioration | 2 | 0 | 0 | 0 | 0 | 0 |
Number of Participants with NGM120/Placebo-Related Treatment Emergent Adverse Events
| Participants | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg |
|---|---|---|---|---|---|---|
| To Determine the Safety and Tolerability of NGM120 in Subjects | 1 | 6 | 6 | 17 | 12 | 2 |
Discontinuation of investigational product due to toxicity
| Participants | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg |
|---|---|---|---|---|---|---|
| To Determine the Safety and Tolerability of NGM120 | 2 | 0 | 2 | 8 | 3 | 0 |
Local injection-site symptom assessment as evidenced by incidence of injection-site reactions
| Participants | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg |
|---|---|---|---|---|---|---|
| To Determine the Safety and Tolerability of NGM120 | 0 | 1 | 0 | 4 | 0 | 0 |
Collected over 3 years, 8 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 NGM120 30mg | 3/10 (30%) | 5/10 (50%) | 10/10 (100%) |
| Part 1 NGM120 100mg | 1/10 (10%) | 3/10 (30%) | 10/10 (100%) |
| Part 2 NGM120 30mg | 3/10 (30%) | 5/10 (50%) | 10/10 (100%) |
| Part 2 NGM120 100mg | 19/31 (61.3%) | 26/31 (83.9%) | 31/31 (100%) |
| Part 2 Placebo | 17/20 (85%) | 10/20 (50%) | 20/20 (100%) |
| Part 3 NGM120 100mg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg |
|---|---|---|---|---|---|---|
| SepsisInfections and infestations | 2/10 | 1/10 | 1/10 | 3/31 | 1/20 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 0/10 | 2/10 | 0/31 | 0/20 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 0/10 | 0/10 | 0/10 | 1/31 | 1/20 | 1/6 |
| Fibula fractureInjury, poisoning and procedural complications | 0/10 | 0/10 | 0/10 | 0/31 | 0/20 | 1/6 |
| Tibia fractureInjury, poisoning and procedural complications | 0/10 | 0/10 | 0/10 | 0/31 | 0/20 | 1/6 |
| SinusitisInfections and infestations | 0/10 | 0/10 | 1/10 | 0/31 | 0/20 | 0/6 |
| Abdominal PainGastrointestinal disorders | 1/10 | 0/10 | 0/10 | 0/31 | 0/20 | 0/6 |
| Rectal haemorrhageGastrointestinal disorders | 1/10 | 0/10 | 0/10 | 0/31 | 0/20 | 0/6 |
| ColitisGastrointestinal disorders | 0/10 | 0/10 | 1/10 | 2/31 | 1/20 | 0/6 |
| Abdominal PainGastrointestinal disorders | 0/10 | 0/10 | 0/10 | 1/31 | 2/20 | 0/6 |
| Event | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg |
|---|---|---|---|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 0/10 | 0/10 | 8/10 | 6/31 | 6/20 | 0/6 |
| FatigueGeneral disorders | 4/10 | 2/10 | 7/10 | 22/31 | 11/20 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 2/10 | 1/10 | 7/10 | 15/31 | 8/20 | 1/6 |
| NauseaGastrointestinal disorders | 2/10 | 2/10 | 7/10 | 13/31 | 8/20 | 0/6 |
| Oedema peripheralGeneral disorders | 2/10 | 2/10 | 7/10 | 13/31 | 7/20 | 2/6 |
| PyrexiaGeneral disorders | 0/10 | 3/10 | 6/10 | 14/31 | 4/20 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 3/10 | 2/10 | 5/10 | 16/31 | 11/20 | 2/6 |
| Neutrophil count decreasedInvestigations | 0/10 | 1/10 | 5/10 | 13/31 | 9/20 | 0/6 |
| Weight decreasedInvestigations | 2/10 | 1/10 | 5/10 | 10/31 | 6/20 | 0/6 |
| HeadacheNervous system disorders | 1/10 | 2/10 | 5/10 | 6/31 | 2/20 | 0/6 |
| Age, Categorical(Participants) | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 2 | 2 | 11 | 4 | 1 | 27 |
| >=65 years | 3 | 8 | 8 | 20 | 16 | 5 | 60 |
| Age, Continuous(years) | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 58.8 ± 9.08 | 65.6 ± 12.21 | 67.7 ± 8.27 | 67.0 ± 9.06 | 69.9 ± 8.10 | 69.0 ± 11.92 | 67.2 ± 8.78 |
| Sex: Female, Male(Participants) | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 1 | 8 | 13 | 11 | 0 | 37 |
| Male | 6 | 9 | 2 | 18 | 9 | 6 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 2 | 0 | 1 | 1 | 7 |
| Not Hispanic or Latino | 8 | 9 | 7 | 30 | 15 | 4 | 73 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 4 | 1 | 7 |
| Race (NIH/OMB)(Participants) | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 2 | 1 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 2 | 0 | 3 |
| Black or African American | 0 | 2 | 1 | 4 | 0 | 1 | 8 |
| White | 8 | 8 | 4 | 17 | 11 | 5 | 53 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 5 | 7 | 6 | 0 | 19 |
| BMI(kg/m2) | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 24.93 ± 5.759 | 26.46 ± 4.636 | 26.53 ± 9.694 | 25.72 ± 5.119 | 25.04 ± 5.113 | 31.20 ± 5.852 | 26.03 ± 5.89 |
| Metastatic Disease(Participants) | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg | Total |
|---|---|---|---|---|---|---|---|
| Yes | 9 | 10 | 10 | 29 | 19 | 6 | 83 |
| No | 1 | 0 | 0 | 2 | 1 | 0 | 4 |
| Sites of Metastases(count of metastatic sites) | Part 1 NGM120 30mg | Part 1 NGM120 100mg | Part 2 NGM120 30mg | Part 2 NGM120 100mg | Part 2 Placebo | Part 3 NGM120 100mg | Total |
|---|---|---|---|---|---|---|---|
| Bone | 3 | 6 | 1 | 1 | 0 | 5 | 16 |
| Liver | 5 | 4 | 5 | 17 | 16 | 0 | 47 |
| Lung | 2 | 4 | 4 | 10 | 5 | 1 | 26 |
| Peritoneum | 2 | 0 | 2 | 2 | 0 | 0 | 6 |
| Other | 2 | 2 | 1 | 5 | 3 | 2 | 15 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Sep 2023, 47 months.
Results were first posted in May 2025, 1 year 8 months after primary completion.
Of 114 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's 47 months is close to that.
Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 36 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-GFRAL Monoclonal Antibody NGM120